Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination

Two large pivotal phase III studies demonstrated the efficacy of the tetravalent dengue vaccine (CYD-TDV; Dengvaxia®, Sanofi Pasteur) against all dengue serotypes. Here we present an unprecedented integrated summary of the immunogenicity of CYD-TDV to identify the parameters driving the neutralizing...

Full description

Bibliographic Details
Main Authors: Claire Vigne, Martin Dupuy, Aline Richetin, Bruno Guy, Nicholas Jackson, Matthew Bonaparte, Branda Hu, Melanie Saville, Danaya Chansinghakul, Fernando Noriega, Eric Plennevaux
Format: Article
Language:English
Published: Taylor & Francis Group 2017-09-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
dengue
vaccine
flaviviruses
immunogenicity
antibody
titers
antibody persistence
Online Access:http://dx.doi.org/10.1080/21645515.2017.1333211

Internet

http://dx.doi.org/10.1080/21645515.2017.1333211

Similar Items